Janux pairs up with Merck for $1B-plus T-cell engager deal

San Diego biotech Janux Therapeutics has penned a major biobucks R&D pact focused on next generation T-cell engager immunotherapies in cancer.

Merck will tap Janux’s so-called Tumor Activated T Cell Engager (TRACTr) tech to engineer new, T-cell engager drug candidates against two cancer targets selected by Merck.